Literature DB >> 1522221

Human bactericidal/permeability-increasing protein and a recombinant NH2-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria.

J Weiss1, P Elsbach, C Shu, J Castillo, L Grinna, A Horwitz, G Theofan.   

Abstract

The bactericidal/permeability-increasing protein (BPI) of neutrophils and BPI fragments neutralize the effects of isolated Gram-negative bacterial lipopolysaccharides both in vitro and in vivo. Since endotoxin most commonly enters the host as constituents of invading Gram-negative bacteria, we raised the question: Can BPI and its bioactive fragments also protect against whole bacteria? To determine whether the bactericidal and endotoxin-neutralizing activities of BPI/fragments are expressed when Gram-negative bacteria are introduced to the complex environment of whole blood we examined the effects of added BPI and proteolytically prepared and recombinant NH2-terminal fragments on: (a) the fate of serum-resistant encapsulated Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa that survive the antibacterial actions of whole blood and (b) the ability of these bacteria to trigger cytokine release. Added BPI in nanomolar concentrations killed each of three encapsulated strains of E. coli and in closely parallel fashion inhibited tumor necrosis factor (TNF) release. Holo-BPI and its NH2-terminal fragment were equipotent toward a rough LPS chemotype K1-encapsulated strain, but the fragment was substantially more potent than holo-BPI toward two encapsulated smooth LPS chemotype strains. TNF release induced by K. pneumoniae and P. aeruginosa was also inhibited by both holo-BPI and fragment but, at the protein concentrations tested, P. aeruginosa was killed only by the fragment and K. pneumoniae was not killed by either protein. The bactericidal action of BPI/fragment toward E. coli is inhibited by C7-depleted serum, but accelerated by normal serum, indicating that BPI, acting in synergy with late complement components, enhances extracellular killing of serum-resistant bacteria. Thus, BPI and an even more potent NH2-terminal fragment may protect against Gram-negative bacteria in the host by blocking bacterial proliferation as well as endotoxin-mediated effects, not only as components of the intracellular antibacterial arsenal of the neutrophil, but also as potentially therapeutic extracellular agents.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1522221      PMCID: PMC329974          DOI: 10.1172/JCI115930

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  46 in total

1.  Priming of polymorphonuclear granulocytes by lipopolysaccharides and its complexes with lipopolysaccharide binding protein and high density lipoprotein.

Authors:  K Vosbeck; P Tobias; H Mueller; R A Allen; K E Arfors; R J Ulevitch; L A Sklar
Journal:  J Leukoc Biol       Date:  1990-02       Impact factor: 4.962

2.  Formation of transmural complement pores in serum-sensitive Escherichia coli.

Authors:  S Bhakdi; G Kuller; M Muhly; S Fromm; G Seibert; J Parrisius
Journal:  Infect Immun       Date:  1987-01       Impact factor: 3.441

3.  Comparison of granule proteins from human polymorphonuclear leukocytes which are bactericidal toward Pseudomonas aeruginosa.

Authors:  K R Wasiluk; K M Skubitz; B H Gray
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

4.  Differential induction of tumor necrosis factor by bacteria expressing rough and smooth lipopolysaccharide phenotypes.

Authors:  N M Kelly; L Young; A S Cross
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

Review 5.  Molecular genetics of membrane phospholipid synthesis.

Authors:  C R Raetz
Journal:  Annu Rev Genet       Date:  1986       Impact factor: 16.830

6.  A family of lipopolysaccharide binding proteins involved in responses to gram-negative sepsis.

Authors:  P S Tobias; J C Mathison; R J Ulevitch
Journal:  J Biol Chem       Date:  1988-09-25       Impact factor: 5.157

7.  Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.

Authors:  E J Ziegler; C J Fisher; C L Sprung; R C Straube; J C Sadoff; G E Foulke; C H Wortel; M P Fink; R P Dellinger; N N Teng
Journal:  N Engl J Med       Date:  1991-02-14       Impact factor: 91.245

8.  Pseudomonas aeruginosa variants isolated from patients with cystic fibrosis are killed by a bactericidal protein from human polymorphonuclear leukocytes.

Authors:  C M Siefferman; W E Regelmann; B H Gray
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

9.  Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents.

Authors:  G D Martich; R L Danner; M Ceska; A F Suffredini
Journal:  J Exp Med       Date:  1991-04-01       Impact factor: 14.307

10.  Endotoxin-neutralizing properties of the 25 kD N-terminal fragment and a newly isolated 30 kD C-terminal fragment of the 55-60 kD bactericidal/permeability-increasing protein of human neutrophils.

Authors:  C E Ooi; J Weiss; M E Doerfler; P Elsbach
Journal:  J Exp Med       Date:  1991-09-01       Impact factor: 14.307

View more
  61 in total

Review 1.  A neutrophil-derived anti-infective molecule: bactericidal/permeability-increasing protein.

Authors:  O Levy
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

2.  Determinants of activation by complement of group II phospholipase A2 acting against Escherichia coli.

Authors:  L M Madsen; M Inada; J Weiss
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

3.  A killed, genetically engineered derivative of a wild-type extraintestinal pathogenic E. coli strain is a vaccine candidate.

Authors:  Thomas A Russo; Janet M Beanan; Ruth Olson; Stacy A Genagon; Ulrike MacDonald; John J Cope; Bruce A Davidson; Brian Johnston; James R Johnson
Journal:  Vaccine       Date:  2007-02-05       Impact factor: 3.641

Review 4.  Bacteria in the intestine, helpful residents or enemies from within?

Authors:  Geraldine O Canny; Beth A McCormick
Journal:  Infect Immun       Date:  2008-05-12       Impact factor: 3.441

5.  The role of liver and kidney on the pharmacokinetics of a recombinant amino terminal fragment of bactericidal/permeability-increasing protein in rats.

Authors:  R J Bauer; K Der; N Ottah-Ihejeto; J Barrientos; A H Kung
Journal:  Pharm Res       Date:  1997-02       Impact factor: 4.200

6.  Role of endotoxin in acute inflammation induced by gram-negative bacteria: specific inhibition of lipopolysaccharide-mediated responses with an amino-terminal fragment of bactericidal/permeability-increasing protein.

Authors:  F R Kohn; A H Kung
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

7.  Lipopolysaccharide-induced E-selectin expression requires continuous presence of LPS and is inhibited by bactericidal/permeability-increasing protein.

Authors:  K Huang; D M Fishwild; H M Wu; R L Dedrick
Journal:  Inflammation       Date:  1995-06       Impact factor: 4.092

8.  Protection against endotoxic shock by bactericidal/permeability-increasing protein in rats.

Authors:  H Jin; R Yang; S Marsters; A Ashkenazi; S Bunting; M N Marra; R W Scott; J B Baker
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

9.  Extracellular accumulation of potently microbicidal bactericidal/permeability-increasing protein and p15s in an evolving sterile rabbit peritoneal inflammatory exudate.

Authors:  Y Weinrauch; A Foreman; C Shu; K Zarember; O Levy; P Elsbach; J Weiss
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

10.  The role of bactericidal/permeability-increasing protein in the treatment of primate bacteremia and septic shock.

Authors:  M A Rogy; H S Oldenburg; S E Calvano; W J Montegut; S A Stackpole; K J Van Zee; M N Marra; R W Scott; J J Seilhammer; L L Moldawer
Journal:  J Clin Immunol       Date:  1994-03       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.